Seven out of 10 men admitted to hospital for a heart attack (acute ST segment elevation myocardial infarction (STEMI)) had erectile dysfunction (ED) in the six months prior to their admission according to new data presented at the World Congress of Cardiology (WCC) Scientific Sessions in Beijing, China. A year-long study conducted in 2009 involving 111 sexually active men at the University Malaya Medical Centre, admitted for STEMI, demonstrated that 75.7 per cent had experienced ED in the six months prior to be hospitalized and all patients with a prior history of ischemic heart disease had ED (Fisher Exact Test, p=0.020). Moreover, 24.7 per cent of the 81 sexually inactive men that were not recruited to the study reported complete ED for more than six months prior to screening. ED and coronary artery disease (CAD) share many common risk factors and are closely related.
NexMed, Inc. (Nasdaq: NEXMD), a specialty CRO with a pipeline of product candidates based on the NexACT® technology, announced that the Japanese Patent Office has issued the Decision to Grant a Patent for NexMed's patent application entitled, "Prostaglandin Compositions for the Treatment of Male Erectile Dysfunction." This patent, when issued, will provide Japanese patent protection to September 2021 and is one in a series of patents and pending applications that NexMed owns on Vitaros® and the underlying NexACT technology. Commenting on today's news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, "We are very pleased with our first patent allowance for Vitaros in Japan. Throughout its history, the Company has aggressively pursued intellectual property coverage for its technology and products under development.
Physicians who prescribe erectile dysfunction drugs for their male patients should be sure to discuss the importance of safer sex practices, even with older patients: that is an important implication of a report in the July 6 issue of Annals of Internal Medicine. The analysis of insurance records of more than 1.4 million U.S. men over 40 found that those who used ED drugs were more likely to have sexually transmitted diseases than were non-users. "Anyone who does not practice safer sex, no matter their age, can contract an STD, " says Anupam B. Jena, MD, PhD, of the Massachusetts General Hospital (MGH) Department of Medicine, the study's lead author. "Even though STDs are quite rare among older men - on the order of 1 per 1, 000 individuals - we found that STD rates in men who used ED drugs were two to three times higher, both before and after they filled their first prescription.
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced that the United States Patent and Trademark Office issued a patent on May 18, 2010, for the method for treatment of premature ejaculation using dapoxetine. Furiex developed dapoxetine in collaboration with Alza Corporation and its affiliates. U.S. Patent No. 7, 718, 705 includes claims directed to dosing dapoxetine on an as-needed basis, capturing the advantage dapoxetine has over other compounds in the same class, which require a pre-loading period for efficacy. The patent will expire in 2022. Furiex has received grants of similar patent claims in over 45 countries around the world including major and emerging markets. Alza's affiliate, Janssen-Cilag, currently markets dapoxetine under the trademark, PRILIGYTM, in a number of markets outside the United States.
VIVUS, Inc. (Nasdaq: VVUS) announced that the positive results from REVIVE-RP (TA-303), a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C. The meeting is jointly sponsored by the International Society for Sexual Medicine (ISSM) and the Sexual Medicine Society of North America (SMSNA). John Mulhall, M.D., Director of the Male Sexual & Reproductive Medicine Program at the Memorial Sloan Kettering Cancer Center in New York, will present the results during the peer-reviewed, moderated poster session. Avanafil met all primary endpoints by demonstrating improvements from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP 2 and SEP 3) and improvement in the erectile function domain of International Index of Erectile Function (IIEF).